Alpine Immune Sciences Appoints Stanford Peng to President and Head of Research and Development
April 18 2019 - 08:00AM
Business Wire
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) (“Alpine”), a
leading clinical-stage immunotherapy company focused on developing
innovative treatments for cancer, autoimmune/inflammatory, and
other diseases, today announced Stanford Peng, M.D. Ph.D., has been
appointed President and Head of Research and Development of Alpine,
effective April 16, 2019.
Dr. Peng, who served as Alpine’s Executive Vice President of
Research & Development and Chief Medical Officer since 2016,
succeeds Mark Litton, Ph.D., whose role as President and Chief
Operating Officer ended effective April 16, 2019.
“It is with great pleasure I announce Stanford’s appointment to
the role of President and Head of Research and Development,” said
Mitchell H. Gold, M.D., Executive Chairman and Chief Executive
Officer of Alpine. “Stanford has a proven ability to consistently
execute at a high level. Under his leadership, Alpine defined a
clear research and development pathway, driving our lead
autoimmune/inflammatory program, ALPN-101, into the clinic earlier
this year and advancing ALPN-202, our lead oncology program, which
we expect to submit for authorization to begin clinical trials
later this year. As a practicing physician, patients are truly the
focus behind Stanford’s drive—a drive he has instilled within the
entire Alpine organization from day one. It’s a privilege to
continue working together in his expanded role.”
“I am honored to be appointed to this new role,” said Dr. Peng.
“This is a particularly exciting time for Alpine as we continue to
advance our programs towards and into the clinic. I look forward to
continuing to work alongside the Alpine team in our shared mission
of bringing novel, meaningful therapies to patients.”
“On behalf of Alpine’s Board and the entire company, I want to
thank Mark for his contributions during his time as President and
Chief Operating Officer. We wish him the very best in his next
endeavors,” said Dr. Gold.
Dr. Peng is an industry veteran with basic, clinical, and
biomedical research and development experience across large pharma,
startups, biotech, academia, and clinical practice. Prior to
joining Alpine, he was Chief Medical Officer at StemCentrx, where
he provided strategic oversight of the company’s clinical and
translational programs prior to its acquisition by AbbVie. Earlier,
he served as Executive Medical Director and Head of Inflammation
and Translational Medicine at Seattle Genetics, Head of the
Rheumatology Clinical Research Unit and Clinical Associate Member
at the Benaroya Research Institute in Seattle, and held various
senior positions at ARYx Therapeutics and Roche. Dr. Peng has also
held clinical positions as a member physician at Virginia Mason
Medical Center in Seattle and as an assistant professor in the
Division of Rheumatology at the Washington University School of
Medicine in St. Louis, Missouri. Dr Peng received his BA in Music
and BS in Biological Sciences from Stanford University, his M.D.
from Yale University School of Medicine, and his Ph.D. in biology
from Yale University. He completed his residency in internal
medicine at the Hospital of the University of Pennsylvania School
of Medicine in Philadelphia followed by a clinical and research
fellowship in rheumatology at Brigham and Women’s Hospital in
Boston.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave
of functional immune therapeutics. Alpine is employing directed
evolution to create potentially powerful multifunctional
immunotherapies to improve patients’ lives. Alpine has two lead
programs. The first, ALPN-101 for autoimmune/inflammatory diseases,
is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic
immune responses. The second, ALPN-202 for cancer, is a dual
PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator
intended to combine checkpoint inhibition with T cell costimulation
– an approach currently absent from approved checkpoint therapies.
Alpine is backed by world-class research and development
capabilities, a highly-productive scientific platform, and a proven
management team. For more information, visit
www.alpineimmunesciences.com.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies, the potential future
development plans of our product candidates and our ability to
successfully develop and achieve milestones in our development
programs. Forward-looking statements generally include statements
that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as “may,” “will,”
“should,” “would,” “expect,” “plan,” “intend,” and other similar
expressions among others. These forward-looking statements are
based on current assumptions that involve risks, uncertainties and
other factors that may cause actual results, events or developments
to be materially different from those expressed or implied by such
forward-looking statements. These risks and uncertainties, many of
which are beyond our control, include, but are not limited to:
clinical trials may not demonstrate safety and efficacy of any of
our product candidates; our ongoing discovery and pre-clinical
efforts may not yield additional product candidates; our
discovery-stage and pre-clinical programs may not advance into the
clinic or result in approved products; any of our product
candidates may fail in development, may not receive required
regulatory approvals, or may be delayed to a point where they are
not commercially viable; we may not achieve additional milestones
in our proprietary or partnered programs; the impact of
competition; adverse conditions in the general domestic and global
economic markets; as well as the other risks identified in our
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and we
undertake no obligation to update forward-looking statements, and
readers are cautioned not to place undue reliance on such
forward-looking statements.
“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig
Domain,” “vIgD” and the Alpine logo are registered trademarks or
trademarks of Alpine Immune Sciences, Inc. in various
jurisdictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190418005307/en/
Investor Relations:Pure CommunicationsCourtney Dugan,
212-257-6723cdugan@purecommunications.comMedia Relations:Pure
CommunicationsJennifer Paganelli, 347-658-8290jpaganelli@purecommunications.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Mar 2023 to Mar 2024